JPRN-jRCT2041210129招募中1 期
Phase Ib/II Study of the Combination of Tucidinostat and Rituximab in Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma - ME2205-1
Hatake Kiyohiko0 个研究点目标入组 71 人开始时间: 2022年1月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Part A: Patients with diagnosed B-NHL, Part B: Patients with diagnosed DLBCL
- •2) Patients who have relapsed or refractory following at least one systemic therapy
- •3) Patients who have had response to a previous treatment regimen that included anti CD20 therapy at least once
- •4) Patients who have normal systemic organ function
排除标准
- •1) Patients with known double hit/triple hit lymphoma
- •2) Patients with bulky disease
- •3) Patients with a history or findings of cardiac disorders
- •4) Patients with gastrointestinal disorders or dysphagia which could affect oral medicine administration and absorption
- •5) Patients with a history of clinically significant pulmonary disorders (including interstitial lung disease, pneumonitis, obstructive pulmonary disease, and bronchospasm)
- •6) Patients with a history of or complications of other malignancies that have not been in remission for at least the last 5 years (except some cases)
- •7) Patients who are deemed by the principal investigator or sub-investigator to be unsuitable for participation in the study due to significant clinical findings, abnormal laboratory results, psychiatric disorders, or other conditions that could affect the results of the study
研究者
相似试验
招募中
2 期
Phase II tucidinostat study for rrPTCJPRN-jRCTs061220060Suzuki Ritsuro46
进行中（未招募）
1 期
Tucatinib and trastuzumab in solid tumors with HER2 alterationsPreviously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 AlterationsMedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10017614Term: Gallbladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10025697Term: Malignant neoplasm of ampulla of VaterSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10008342Term: Cervix carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10046766Term: Uterine cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004873-29-PLSeagen Inc.270
招募中
1 期
Tucatinib and trastuzumab in solid tumors with HER2 alterationsPreviously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 AlterationsMedDRA version: 20.0Level: PTClassification code: 10008593Term: Cholangiocarcinoma Class: 100000004864CTIS2024-511481-37-00Seagen Inc.164
进行中（未招募）
2 期
Basket study of tucatinib and trastuzumab in solid tumors with HER2 alterationsCervical, Uterine, biliary tract, urothelial Cancers, NSCLC, Breast Cancer - Other solid tumorsJPRN-jRCT2031210113Ramos Jorge20
进行中（未招募）
1 期
Tucatinib and trastuzumab in solid tumors with HER2 alterationsPreviously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 AlterationsMedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10017614Term: Gallbladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10025697Term: Malignant neoplasm of ampulla of VaterSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10008342Term: Cervix carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10046766Term: Uterine cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004873-29-DESeagen Inc.270